Results 201 to 210 of about 377,160 (316)

Genetic Code Expanded T Cell for Controllable Immunotherapy

open access: yesAdvanced Science, EarlyView.
Our GCE‐CAR‐T cells enables tight, dose‐dependent, and function‐preserving control of CAR expression at the translational level through amber codon suppression and genetic incorporation of ncAA. ABSTRACT Chimeric antigen receptor (CAR)‐T cell therapy has demonstrated curative potential against hematologic malignancies, but its clinical application ...
Xue Wang   +4 more
wiley   +1 more source

From legacy to innovation: A comprehensive review of vaccine platforms against viral infections. [PDF]

open access: yesVirus Res
Farsiu N   +8 more
europepmc   +1 more source

Biosynthesis of Sciadonic Acid Derived from Gymnosperms with Anti‐Colitis Activity

open access: yesAdvanced Science, EarlyView.
This study establishes an efficient Yarrowia lipolytica platform for unusual sciadonic acid (SCA) production and assess the anti‐colitis efficacy in mice of SCA, supporting its potential as a novel therapeutic lipid. ABSTRACT Sciadonic acid (SCA), Δ5‐unsaturated fatty acid with anti‐inflammatory and lipid‐regulatory properties, is predominantly derived
Yadi Gao   +10 more
wiley   +1 more source

Current Status and Evolution of Immunotherapy in Glioma Management. [PDF]

open access: yesInt J Med Sci
Liu J   +8 more
europepmc   +1 more source

Herba Lysimachiae Polysaccharide‐Modified Selenium Nanoparticles Alleviate Oxidative Injury in Kidney Stones via TOMM22‐Regulated Mitophagy Activation

open access: yesAdvanced Science, EarlyView.
HLP‐SeNPs, a Lysimachia christinae polysaccharide‐modified selenium nanoparticle, treat kidney stones by downregulating TOMM22 expression, which reduces PINK1 translocation into mitochondria and promotes its retention on the outer mitochondrial membrane.
Junyi Yang   +10 more
wiley   +1 more source

Nucleic Acid Therapeutics for “Undruggable” Cancer Targets: Mechanisms, Challenges, and Prospects

open access: yesAdvanced Science, EarlyView.
Nucleic acid therapeutics bypass the structural limitations of conventional drugs by targeting mRNA rather than proteins. This review examines how antisense oligonucleotides, siRNAs, miRNAs, aptamers, and mRNA vaccines intervene against historically undruggable oncoproteins including Ras, MYC, and p53, highlighting mechanistic advances, delivery ...
Feng Xu   +6 more
wiley   +1 more source

Oncolytic viruses in lung cancer: mechanisms of action and research progress. [PDF]

open access: yesFront Microbiol
Ji T   +6 more
europepmc   +1 more source

Synergistic Remodeling of Tumor Immune Microenvironment via a DNA Nanodevice Integrating STING Activation and Lysosome‐Targeted PD‐L1 Degradation

open access: yesAdvanced Science, EarlyView.
A rational design DNA nanoplatform not only achieves efficient PD‐L1 degradation but also triggers robust STING signaling. The nanodevice effectively reprograms “cold” tumors, leading to potent inhibition of tumor growth and metastasis in vivo. ABSTRACT The cGAS‐STING pathway is a cornerstone of innate antitumor immunity; however, its therapeutic ...
Haoxiang Li   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy